The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy.
 
Mark Blaine Geyer
No Relationships to Disclose
 
Jae Hong Park
Consulting or Advisory Role - Amgen; Juno Therapeutics
Research Funding - Genentech/Roche (Inst); Juno Therapeutics (Inst)
 
Isabelle Riviere
Stock and Other Ownership Interests - Juno Therapeutics
Consulting or Advisory Role - Juno Therapeutics
Research Funding - Juno Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalty sharing agreement
Travel, Accommodations, Expenses - Juno Therapeutics
 
Xiuyan Wang
No Relationships to Disclose
 
Terence Purdon
No Relationships to Disclose
 
Michel Sadelain
Stock and Other Ownership Interests - Juno Therapeutics
Consulting or Advisory Role - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Licensed patent to Juno Therapeutics.
 
Renier J. Brentjens
Stock and Other Ownership Interests - JUNO Therapeutics
Consulting or Advisory Role - JUNO Therapeutics
Research Funding - JUNO Therapeutics
Patents, Royalties, Other Intellectual Property - Scientific Cofounder of JUNO therapeutics